FDA Brief

Warning letters Drugs

FDA warning letter to

Microbiological Testing & Consulting, LLC

High riskIssued Mar 16Posted Mar 31Center for Drug Evaluation and Research (CDER)

FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.

What happened

FDA inspected the contract testing laboratory in Alsip, IL, from September 8 to 16, 2025. FDA found the firm failed to use scientifically sound laboratory controls, lacked key documentation for microbiological tests, inadequately qualified growth media, and did not adequately oversee quality, investigations, training, or data integrity. The firm's response to the Form FDA 483 was inadequate.

What FDA found

  1. The firm lacked scientifically sound laboratory controls and did not perform appropriate testing to ensure drug products were free of objectionable microorganisms.

    21 CFR 211.160(b); 21 CFR 211.165(b)
  2. Microbiological test records routinely omitted equipment number, sample size, media batch number, dilutions, incubation temperatures, and the analyst’s name or signature.

    21 CFR 211.160(b)
  3. The firm did not adequately qualify growth media, including screening for inhibitory properties, so its microbiological results were not reliable.

    21 CFR 211.160(b)
  4. The quality control unit did not adequately oversee laboratory testing, documentation, investigations, or analyst competency.

    21 CFR 211.22
  5. The firm could not provide records of regular CGMP training and did not show immediate steps to train employees or stop testing until training was complete.

  6. The firm’s quality system did not adequately ensure data accuracy and integrity, and FDA found a discrepancy between OOS/OOL investigations provided to FDA and those provided to a customer.

    Section 501(a)(2)(B) of the FD&C Act; 21 CFR parts 210 and 211

What FDA wants

Respond in writing within 15 working days with corrective actions, including independent assessments, retrospective reviews, CAPA plans, and data integrity remediation. If corrective actions cannot be completed, state the reasons and your schedule for completion.

Who should pay attention

  • drug manufacturers that use this contract testing laboratory
  • companies relying on third-party microbiological test results
  • quality teams that review certificates of analysis from contract labs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk